OKYO Pharma (Nasdaq: OKYO) reported that Chairman Gabriele Cerrone, via Panetta Partners, purchased 25,000 ordinary shares at $1.40 per share. According to OKYO Pharma, this increases his total holding to 10,851,416 shares, representing 20.51% of the company’s issued share capital.
The clinical-stage biopharmaceutical company focuses on therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. OKYO plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
Loading...
Loading translation...
Positive
25,000-share insider purchase at $1.40 by the Chairman
Chairman’s total holding at 10,851,416 shares or 20.51% of capital
Planned global Phase 3 pivotal trial for urcosimod in NCP
Phase 3 trial to enroll approximately 111 patients in single-dose regimen study
Negative
None.
News Market Reaction – OKYO
+5.11%
6 alerts
+5.11%Session close to close
+9.0%Peak in 24 hr 54 min
$75.05MMarket Cap
0.9xRel. Volume
In the Jul 21 session, OKYO gained 5.11%, reflecting a notable positive market reaction.
Argus tracked a peak move of +9.0% during that session.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +5.1% in the session following this news. -5.14% followed OKYO's July 8 FDA Type D a...
Analysis
The stock moved +5.1% in the session following this news. -5.14% followed OKYO's July 8 FDA Type D announcement, providing a historical comparison for this chairman share purchase. The active F-3 shelf permits offerings up to $200,000,000, representing a sourced financing risk.
Key Figures
Shares purchased:25,000 ordinary sharesPurchase price:$1.40 per shareTotal holding:10,851,416 ordinary shares+3 more
Company announced Phase 2 urcosimod data presentation during ASCRS
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive announcements were followed by divergent reactions in two of three comparable events, while informational announcements produced mixed outcomes.
"therapies for the treatment of neuropathic corneal pain (NCP)"
Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.
Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.
single-dose regimenmedical
"evaluate a single-dose regimen of urcosimod"
A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.
pivotal clinical trialmedical
"initiate a global Phase 3 pivotal clinical trial"
A pivotal clinical trial is a late-stage medical study designed to provide the main evidence regulators use to decide whether a drug or medical device can be approved and sold; think of it as the product’s final exam. For investors, the trial’s outcome is critical because a clear pass can unlock regulatory approval, market access and future revenue, while failure can halt commercialization and materially affect a company’s valuation.
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital.
About OKYOPharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com
FAQ
What insider share purchase did OKYO Pharma (NASDAQ: OKYO) announce on July 21, 2026?
OKYO Pharma announced its Chairman Gabriele Cerrone bought 25,000 ordinary shares at $1.40 per share. According to OKYO Pharma, the purchase was made through Panetta Partners, an entity in which he has a beneficial interest, increasing his overall ownership stake.
How many OKYO Pharma shares does Chairman Gabriele Cerrone now own after the latest purchase?
After the 25,000-share purchase, Chairman Gabriele Cerrone holds 10,851,416 ordinary shares of OKYO Pharma. According to OKYO Pharma, this position represents 20.51% of the company’s issued share capital, indicating a significant insider ownership level following the transaction.
What is the planned Phase 3 trial for urcosimod at OKYO Pharma (OKYO)?
OKYO Pharma plans a global Phase 3 pivotal trial of urcosimod for neuropathic corneal pain. According to OKYO Pharma, the study will begin in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose treatment regimen in this indication.
When will OKYO Pharma’s Phase 3 trial in neuropathic corneal pain start and how many patients are expected?
The Phase 3 neuropathic corneal pain trial is planned for the second half of this year. According to OKYO Pharma, the global pivotal study will enroll about 111 patients to assess a single-dose regimen of its investigational therapy urcosimod.
What does the Chairman’s 20.51% stake mean for OKYO Pharma (NASDAQ: OKYO) shareholders?
The Chairman now holds 20.51% of OKYO Pharma’s issued share capital following the latest share purchase. According to OKYO Pharma, this reflects increased insider ownership, which some investors view as aligning management interests with shareholders, though it does not guarantee future stock performance.
